While awaiting reports of BCR-ABL, in view of abnormal leukocytosis and thrombocytosis revealed by peripheral study and bone marrow aspirate, the patient was started on therapy hydroxyurea 500 mg (2 g daily in divided doses) with injection low-molecular-weight heparin (40 mg daily). On the availability of the report of BCR-ABL on the 10th day, he commenced on tyrosine kinase inhibitor tablet imatinib 400 mg and tablet Ecosprin and discontinued hydroxyurea therapy. The gene discussed is ABL1; the disease is thrombocytosis disease.